abs432.txt	importance		oral	anticancer	medications	are	increasingly	important	but	costlytreatment	options	for	patients	with	cancer	by	early	2017	43	states	andwashington	dc	had	passed	laws	to	ensure	private	insuranceenrolled	in	fully	insured	health	plans	pay	no	more	medicationsadministered	mouth	than	administered	infusion	federal	legislation	regarding	this	issue	is	currently	pending	despite	theirrapid	acceptance	the	changes	associated	state	adoption	of	chemotherapyparity	have	not	been	described	objective	estimate	medication	use	out-of-pocketspending	and	plan	spending	chemotherapy	parity	lawadoption	design	setting	participants	analysis	administrative	claimsdata	from	2008-2012	3	large	nationwide	insurers	aggregated	carecost	institute	data	was	first	completed	2015	updated	study	population	included	63	780	adults	living	1	16	that	passedparity	during	period	who	received	drug	treatmentfor	which	orally	treatment	were	available	analysisused	a	difference-in-differences	approach	exposures	time	before	after	controlling	whether	patient	enrolled	subject	parity(fully	insured)	or	(self-funded	exempt	via	employee	retirement	incomesecurity	act)	main	outcomes	measures	total	care	results	aged	18	through	64	years	51	4%	participated	infully	48	6%	self-funded	(57	2%	women	76	8%	wereaged	45	years)	as	aproportion	all	increased	18%	22%	(adjusteddifference-in-differences	risk	ratio	[addrr]	04	95%	ci	0	96-1	13	p	=	34)comparing	months	vs	theproportion	prescription	fills	therapy	withoutcopayment	15	0%	53	double	increase(12	3%-18	0%)	(p	<	001)	proportion	ofpatients	out-of-pocket	$100	per	month	from8	11	1%	compared	slight	decline	12	7%	notsubject	004)	estimated	monthlyout-of-pocket	decreased	$19	44	at	25th	percentile	$32	atthe	50th	$10	83	75th	the90th	($37	19)	95th	($143	25)	percentiles	(all	001	parity)	did	notincrease	6-month	users	any	usersof	alone	conclusions	relevance	while	modestly	improvedfinancial	protection	many	without	increasing	carespending	these	may	be	insufficient	areprotected	high	costs
